Vimarsana
Biggest News Aggregation in the World

Page 2 - Artificial Intelligence Ai Programme News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Artificial Intelligence Ai Programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Artificial Intelligence Ai Programme Today - Breaking & Trending Today

Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza ... - Vimarsana News

Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza ...

Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza ...

Poolbeg Pharma and CytoReason identify "very exciting influenza targets" - Vimarsana News

Poolbeg Pharma and CytoReason identify "very exciting influenza targets"

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington and CytoReason co-founder and CEO David Harel speak to Thomas Warner from Proactive after...

Successful Artificial Intelligence led programme identifies multiple influenza drug targets - Vimarsana News

Successful Artificial Intelligence led programme identifies multiple influenza drug targets

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence ('AI') Programme with ...

Poolbeg Pharma Novel influenza drug targets identified faster with AI programme - Vimarsana News

Poolbeg Pharma Novel influenza drug targets identified faster with AI programme

Poolbeg Pharma Novel influenza drug targets identified faster with AI programme

Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022 - Vimarsana News

Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2022

Results for the year ended 31 December 2022 Significant milestones reached, well capitalised and positioned for future growth LONDON, UK / ACCESSWIRE / March